Alzheimer’s drug lecanemab receives accelerated approval amid safety concerns | CNN
The FDA granted accelerated approval for lecanemab, marketed as Leqembi, an Alzheimer’s drug showing potential to slow cognitive decline. Despite safety concerns like brain swelling and bleeding, it targets the disease's underlying process. Priced at $26,500/year, its Medicare coverage remains uncertain, mirroring restrictions on Aduhelm, its predecessor.
Reference News
Alzheimer’s drug lecanemab receives accelerated approval amid safety concerns | CNN
The FDA granted accelerated approval for lecanemab, marketed as Leqembi, an Alzheimer’s drug showing potential to slow cognitive decline. Despite safety concerns like brain swelling and bleeding, it targets the disease's underlying process. Priced at $26,500/year, its Medicare coverage remains uncertain, mirroring restrictions on Aduhelm, its predecessor.